Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

BACKGROUND: Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Vincenzo, Granetto, Cristina, Falletta, Antonella, Paccagnella, Matteo, Abbona, Andrea, Fea, Elena, Fabozzi, Teresa, Lo Nigro, Cristiana, Merlano, Marco Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081116/
https://www.ncbi.nlm.nih.gov/pubmed/32206180
http://dx.doi.org/10.4251/wjgo.v12.i3.301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081116/
https://www.ncbi.nlm.nih.gov/pubmed/32206180
http://dx.doi.org/10.4251/wjgo.v12.i3.301

Ejemplares similares